Monoclonal antibody therapies in the management of SARS-CoV-2 infection.
| Autor: | Miguez-Rey E; Enfermedades Infecciosas, Hospital Universitario de A Coruña, A Coruña, Spain., Choi D; Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea., Kim S; Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea., Yoon S; Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea., Săndulescu O; Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases 'Prof. Dr. Matei Balș', Bucharest, Romania. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2022 Jan; Vol. 31 (1), pp. 41-58. Date of Electronic Publication: 2022 Feb 14. |
| DOI: | 10.1080/13543784.2022.2030310 |
| Abstrakt: | Introduction: Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants. Areas Covered: This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges associated with the use of these agents. Expert Opinion: NAbs offer an effective, evidence-based therapeutic intervention during the early stages of SARS-CoV-2 infection when viral replication is the primary factor driving disease progression. As the pandemic progresses, appropriate use of NAbs will be important to minimize the risk of escape variants. Ultimately, the availability of effective treatments for COVID-19 will allow the establishment of treatment algorithms for minimizing the substantial rates of hospitalization, morbidity (including long COVID) and mortality currently associated with the disease. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|